Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Assets (2016 - 2026)

Akebia Therapeutics has reported Assets over the past 11 years, most recently at $376.6 million for Q4 2025.

  • Quarterly Assets rose 70.65% to $376.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $376.6 million through Dec 2025, up 70.65% year-over-year, with the annual reading at $376.6 million for FY2025, 70.65% up from the prior year.
  • Assets was $376.6 million for Q4 2025 at Akebia Therapeutics, up from $364.2 million in the prior quarter.
  • Over five years, Assets peaked at $628.7 million in Q1 2021 and troughed at $207.1 million in Q3 2024.
  • The 5-year median for Assets is $350.8 million (2022), against an average of $376.3 million.
  • Year-over-year, Assets crashed 52.12% in 2023 and then soared 75.8% in 2025.
  • A 5-year view of Assets shows it stood at $529.3 million in 2021, then plummeted by 32.74% to $356.1 million in 2022, then plummeted by 32.12% to $241.7 million in 2023, then fell by 8.7% to $220.7 million in 2024, then surged by 70.65% to $376.6 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Assets are $376.6 million (Q4 2025), $364.2 million (Q3 2025), and $345.6 million (Q2 2025).